Researchers tested whether conservative management of adnexal masses classified as benign could lead to subsequent malignant ovarian cancer.
Researchers studied how the anti–PD-L1 agent avelumab fit into the recurrent and refractory ovarian cancer treatment landscape.
A large study looked at previously confirmed and newly discovered associations between several genes and breast cancer and ovarian cancer risk.
Experts weigh in on valuable findings that can be gleaned despite the fact that the phase III trial did not generate clinically meaningful results.
This study was the first in a large, unselected population to assess ovarian mass appearance and the connection to ovarian cancer risk.
In this new study involving a mouse model of ovarian cancer, researchers evaluated the effects of entinostat on adaptive immune responses.
A screening study that began more than 30 years ago looked at ultrasound screening for at-risk women for ovarian cancer and its effects on disease-specific survival.
A pooled analysis of two randomized trials found that neoadjuvant chemotherapy and upfront debulking surgery yield similar outcomes in patients with advanced tubo-ovarian cancer, except in some settings.
Researchers tested whether 2 years of maintenance therapy with olaparib would improve outcomes in advanced ovarian cancer patients.
Regular users of low-dose aspirin appear to have a reduced risk of developing ovarian cancer, according to a new study.